Skip to content
Hair Pipeline
← Recruiting trials
NCT07907783Phase 2Recruiting

Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia

A Randomized, Multicenter, Double-Blind, Vehicle-Controlled, Phase 2 Study to Assess Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia

In the register

The register attaches this trial to PP405 (Pelage Pharmaceuticals), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.

What the registry records

Status
Recruiting
Declared phase
Phase 2
Sponsor
Pelage Pharmaceuticals, Inc.
Participants (registry)
200
Start
November 2026
Primary completion
September 2027 (planned)
Study completion
March 2028 (planned)
Last registry update
November 2026
Countries
United States

Conditions studied: Androgenetic Alopecia

Interventions: PP405 0.05% Topical Gel, PP405, Vehicle Topical Gel, Vehicle

Full record on ClinicalTrials.gov ↗

Other trials of PP405

  • NCT07819435Phase 2/3Recruiting

    Phase 2/3 Efficacy and Safety of PP405 in Adult Males

  • NCT06393452Phase 2Completed

    Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.